SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody […]
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research in bioRxiv entitled, “Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy.” The […]
SOUTH SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal […]
SOUTH SAN FRANCISCO, Calif., April 15, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Generation of recombinant hyperimmune globulins from diverse B cell repertoires,” in the peer-reviewed journal Nature Biotechnology. […]
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) — GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it will present an abstract in a poster session at the 2021 American Association for Cancer Research (AACR) […]
BARCELONA, Spain, March 9, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P;NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people worldwide, today announced the closing of its agreement with GigaGen Inc. to acquire its remaining 56% share capital for USD 80 million. GigaGen […]
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data details the technical […]
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), […]
“One of the reasons we perform single-cell approaches is they allow us to pick up subtle differences that would be missed with more conventional tools,” says David S. Johnson, PhD, CEO and co-founder of GigaGen, a company that specializes in microfluidics and molecular genomics. Two GigaGen platforms, Surge and Magnify, can facilitate the development of […]
GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma. GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end. It calls GIGA-2050 a recombinant hyperimmune product, and said it is akin to recombinant convalescent sera. GigaGen showed […]
A South San Francisco biotech firm has come up with a way to make a COVID-19 therapy without relying on repeat antibody donors using a new class of drugs called “recombinant hyperimmunes.” Ken Bastida reports. (8-10-20) Watch the tv segment.
Blood collected from survivors of COVID-19 has been used to identify antibodies against the disease, which have been turned into experimental drugs to fight it. But it’s not an easy process. So back in March, San Francisco startup GigaGen decided to test a technology it developed to rapidly identify disease-fighting antibodies against SARS-CoV-2, the virus […]
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional […]
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel […]
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020. Read the full press release.
Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients. Read the full story.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19. Read the full story.
Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow. GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves […]
It’s not just people and animals that can produce antibodies. Scientists now have the technology to build what are essentially molecular copying machines that can theoretically churn out large volumes of the antibodies found in recovered patients. At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying […]
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody […]
GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research in bioRxiv entitled, “Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy.” The […]
GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies
SOUTH SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal […]
GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology
SOUTH SAN FRANCISCO, Calif., April 15, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Generation of recombinant hyperimmune globulins from diverse B cell repertoires,” in the peer-reviewed journal Nature Biotechnology. […]
GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) — GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it will present an abstract in a poster session at the 2021 American Association for Cancer Research (AACR) […]
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins
BARCELONA, Spain, March 9, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P;NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people worldwide, today announced the closing of its agreement with GigaGen Inc. to acquire its remaining 56% share capital for USD 80 million. GigaGen […]
GigaGen Announces Publication in the Peer-Reviewed Journal mAbs
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data details the technical […]
GigaGen Initiates Large-Scale Manufacturing of First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), […]
GEN: Drug Targets Identified More Discerningly
“One of the reasons we perform single-cell approaches is they allow us to pick up subtle differences that would be missed with more conventional tools,” says David S. Johnson, PhD, CEO and co-founder of GigaGen, a company that specializes in microfluidics and molecular genomics. Two GigaGen platforms, Surge and Magnify, can facilitate the development of […]
BioCentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute
GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma. GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end. It calls GIGA-2050 a recombinant hyperimmune product, and said it is akin to recombinant convalescent sera. GigaGen showed […]
KPIX-TV (CBS): Bay Area Biotech Company Takes New Approach in COVID-19 Treatment
A South San Francisco biotech firm has come up with a way to make a COVID-19 therapy without relying on repeat antibody donors using a new class of drugs called “recombinant hyperimmunes.” Ken Bastida reports. (8-10-20) Watch the tv segment.
Fierce Biotech: GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests
Blood collected from survivors of COVID-19 has been used to identify antibodies against the disease, which have been turned into experimental drugs to fight it. But it’s not an easy process. So back in March, San Francisco startup GigaGen decided to test a technology it developed to rapidly identify disease-fighting antibodies against SARS-CoV-2, the virus […]
BioSpace: GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional […]
GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel […]
GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020. Read the full press release.
BioPharm International: Plasma-Based Antibody Therapies Battle Against COVID-19
Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients. Read the full story.
San Francisco Business Times: Biotech adapts to new working conditions in the age of Covid-19
Read the full story.
Drug Target Review: Intravenous immunoglobulins, hyperimmunes and pandemic viruses
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19. Read the full story.
Nature Biotechnology: Convalescent serum lines up as first-choice treatment for coronavirus
Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow. GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves […]
TIME: Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
It’s not just people and animals that can produce antibodies. Scientists now have the technology to build what are essentially molecular copying machines that can theoretically churn out large volumes of the antibodies found in recovered patients. At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying […]